Welcome to our dedicated page for ARVINAS SEC filings (Ticker: ARVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ARVINAS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ARVINAS's regulatory disclosures and financial reporting.
Arvinas, Inc. Chief Medical Officer Noah Berkowitz reported an automatic sale of 5,685 shares of common stock at $11.89 per share. The shares were sold by the company to cover tax withholding obligations tied to the vesting and settlement of 25% of his restricted stock units granted on February 13, 2025. The transaction was not a discretionary trade. After this sale, Berkowitz directly holds 163,938 shares of Arvinas common stock.
Arvinas, Inc. Chief Accounting Officer David K. Loomis reported an automatic sale of common stock to cover taxes tied to restricted stock units. On February 13, he sold 1,016 shares of common stock at an average price of $11.89 per share in an open-market transaction.
The footnotes explain this sale was made by the company to satisfy tax withholding obligations upon vesting and settlement of 25% of RSUs granted on February 13, 2025, and that it was not a discretionary trade. After this sale, Loomis directly owns 30,800 shares, including 119 shares previously purchased under the company’s 2018 Employee Stock Purchase Plan.
Arvinas, Inc. President and CEO Randy Teel reports his direct holdings of common stock and stock options in the company. The filing lists multiple option and restricted stock unit grants made between 2018 and 2025, with vesting schedules extending through 2029 and generally contingent on continued service. It also notes shares previously purchased under the 2018 Employee Stock Purchase Plan. The report does not show any stock purchases or sales, only existing equity awards and holdings.
Arvinas, Inc. shareholder plans a modest Rule 144 stock sale. A holder has filed to sell 5,685 shares of Arvinas common stock through Morgan Stanley Smith Barney LLC on or around 02/13/2026 on the NASDAQ.
The filing lists an aggregate market value of 67,605.35 for the shares to be sold, compared with 64,224,294 Arvinas common shares outstanding. The shares were acquired on 02/13/2026 through settlement of vested restricted stock units from Arvinas, Inc.
A shareholder of Arvinas, Inc. has filed a notice to sell 4,592 common shares under Rule 144. The shares are to be sold through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of 54607.52. The issuer had 64224294 shares outstanding, and the approximate sale date is 02/13/2026.
The securities were acquired on 02/13/2026 through settlement of vested restricted stock units from Arvinas, Inc., with payment also dated 02/13/2026 and described as not applicable, indicating no separate cash purchase at that time.
Arvinas, Inc. insider plans small stock sale under Rule 144. A person for whose account the shares are held filed to sell 4,403 shares of Arvinas common stock through Morgan Stanley Smith Barney LLC on or about 02/13/2026 on the NASDAQ market, with an aggregate market value of $52,359.96. These shares were acquired the same day through settlement of vested restricted stock units granted by Arvinas, Inc. The filing notes that shares outstanding were 64,224,294, providing context for the sale’s relative size.
Arvinas, Inc. had an affiliated holder file a Form 144 notice to sell 5,134 shares of its common stock through Morgan Stanley Smith Barney LLC on or about 02/13/2026 on the NASDAQ market. The shares have an aggregate market value of $61,052.92 based on the figures provided.
The securities to be sold arose from the settlement of vested restricted stock units acquired from Arvinas on 02/13/2026, with payment noted as not applicable. Common shares outstanding were 64,224,294 at the time referenced, providing context for the relative size of this planned sale.
Arvinas, Inc. announced a leadership transition, with longtime executive Randy Teel, Ph.D. becoming president, chief executive officer, principal executive officer, and a board member effective February 12, 2026. Former CEO John Houston, Ph.D. resigned from his officer roles but remains a director and will serve as a consultant.
Teel, who joined Arvinas in 2018 and most recently served as chief business officer, will receive a $680,000 annual base salary and a performance-based bonus target equal to 60% of salary. He is also being granted a stock option for 218,691 shares and a restricted stock unit award covering 147,179 shares, both vesting over four years.
The amended employment agreement provides 12 months of salary and health premium support if Teel is terminated without cause or resigns for good reason outside a change in control, and 18 months of salary, health benefit support, a lump sum equal to 150% of target bonus, and full vesting of unvested equity if this occurs within 12 months after a change in control. Houston’s consulting agreement runs through March 1, 2027 and includes a lump-sum COBRA-related payment of $27,914.40, a $457,000 lump sum tied to the 2025 bonus, potential hourly consulting fees, and continued equity vesting.
Arvinas (ARVN) insider update: Chief Accounting Officer David K. Loomis reported a sale of 230 shares of common stock on 11/07/2025 at $9.89 per share. The filing states the sale was made automatically by the company to cover tax withholding tied to the vesting and settlement of 25% of RSUs granted on December 13, 2022.
Following the transaction, Loomis beneficially owns 31,697 shares directly. This total includes 1,239 shares previously purchased under the company’s 2018 Employee Stock Purchase Plan.
Arvinas (ARVN) reported Q3 2025 results with revenue of $41.9 million versus $102.4 million a year ago and a net loss of $35.1 million versus $49.2 million. Year to date, revenue reached $253.1 million, helped by a change in accounting estimate tied to the Pfizer collaboration that increased revenue by $150.2 million and reduced net loss accordingly. The company also recognized $20.0 million upon a Novartis development milestone for luxdegalutamide (ARV-766).
Operating discipline was evident: research and development expense fell to $64.7 million from $86.9 million, and general and administrative expense declined to $21.0 million from $75.8 million. Cash, cash equivalents and marketable securities totaled $787.6 million as of September 30, 2025. Operating cash outflow was $243.4 million for the first nine months.
Arvinas announced a $100.0 million share repurchase program and bought 2,560,030 shares for $20.2 million in Q3, leaving $79.8 million authorized. With Pfizer, the company agreed to jointly select a third party for commercialization and potential further development of vepdegestrant, and implemented workforce reductions to streamline operations.